Clinical trial
A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific…
NCT00001382 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00001382 |
|---|---|
| Title | A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate |
| Official title | A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult Patients With Adenocarcinoma of the Prostate |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Prostatic Neoplasms |
| Intervention type | Biological |
| Interventions | PROSTVAC |
| Enrollment | 75 |
| Start date | Mar 1, 1994 |
| Completion | Mar 1, 2000 |
| First posted | Dec 10, 2002 |
| Last update posted | Mar 4, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: